Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Castleman's disease, an atypical lymphoproliferative disorder, can be classified into 2 types: hyaline-vascular and plasma cell types according to the histologic features of the affected lymph nodes. The plasma cell type is frequently associated with systemic manifestations and is often refractory to systemic therapy including corticosteroids and chemotherapy, particularly in multicentric form. Dysregulated overproduction of interleukin-6 (IL-6) from affected lymph nodes is thought to be responsible for the systemic manifestations of this disease. Therefore, interference with IL-6 signal transduction may constitute a new therapeutic strategy for this disease. We used humanized anti-IL-6 receptor antibody (rhPM-1) to treat 7 patients with multicentric plasma cell or mixed type Castleman's disease. All patients had systemic manifestations including secondary amyloidosis in 3. With the approval of our institution's ethics committee and the consent of the patients, they were treated with 50 to 100 mg rhPM-1 either once or twice weekly. Immediately after administration of rhPM-1, fever and fatigue disappeared, and anemia as well as serum levels of C-reactive protein (CRP), fibrinogen, and albumin started to improve. After 3 months of treatment, hypergammaglobulinemia and lymphadenopathy were remarkably alleviated, as were renal function abnormalities in patients with amyloidosis. Treatment was well tolerated with only transient leukopenia. Histopathologic examination revealed reduced follicular hyperplasia and vascularity after rhPM-1 treatment. The pathophysiologic significance of IL-6 in Castleman's disease was thus confirmed, and blockade of the IL-6 signal by rhPM-1 is thought to have potential as a new therapy based on the pathophysiologic mechanism of multicentric Castleman's disease. (Blood. 2000;95:56-61)
Nishimoto
N
N
Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Suita-city, Osaka, Japan. norihiro@imed3.med.osaka-u.ac.jp
Sasai
M
M
Shima
Y
Y
Nakagawa
M
M
Matsumoto
T
T
Shirai
T
T
Kishimoto
T
T
Yoshizaki
K
K
D000328:Adult; D000686:Amyloidosis; D000740:Anemia; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D005871:Castleman Disease / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D005221:Fatigue; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D019947:Receptors, Interleukin-6 / Q000097:blood / Q000276:immunology*; D012709:Serum Albumin / Q000378:metabolism; D013997:Time Factors
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D012709:Serum Albumin; D005340:Fibrinogen; D002097:C-Reactive Protein